Conditions: Diabetes Mellitus, Type 2
Keywords: Diabetes mellitus HbA1c
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 250
Healthy volunteers: no

Brief summary:
This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of GSK189075 (an SGLT2 inhibitor) compared to placebo, administered over 12 weeks in treatment-naive subjects with type 2 diabetes mellitus

Detailed description:

Arms:
arm 1: Participants will receive GSK189075 for 12 weeks arm 2: Participants will receive GSK189075 matching Placebo for 12 weeks

Interventions: intervention 1: GSK189075 intervention 2: Placebo
Intervention descriptions: intervention 1: GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet intervention 2: Available as Placebo matching tablet to GSK189075

Protocol document: